Teva Pharmaceutical Industries Limited
39.41USD
-0.8000 (-1.99%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TEVA.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.73▲ | $0 | 0 | 0 |
| Next quarter | $0.75▲ | $0 | 0 | 0 |
| Current year | $2.11▲ | $0 | 0 | 0 |
| Next year | $3.09▲ | $0 | 0 | 0 |
280 ratings from 47 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $42 $47 | Oct 15, 2026 |
| JP Morgan | Maintained | Overweight | $40 $50 | Oct 12, 2026 |
| TD Cowen | Initiated | Buy | $55 | Oct 1, 2026 |
| Oppenheimer | Initiated | Outperform | $50 | Sep 23, 2026 |
| Leerink Partners | Initiated | Outperform | $45 | Sep 9, 2026 |
| UBS | Maintained | Buy | $42 $48 | Sep 4, 2026 |
| Barclays | Maintained | Overweight | $40 $42 | Aug 12, 2026 |
| Piper Sandler | Maintained | Overweight | $42 $44 | Jul 28, 2026 |
| Barclays | Maintained | Overweight | $38 $40 | May 6, 2026 |
| JP Morgan | Maintained | Overweight | $35 $40 | Apr 30, 2026 |
| UBS | Maintained | Buy | $36 $42 | Apr 30, 2026 |
| Piper Sandler | Reiterated | Overweight | $41 $42 | Apr 30, 2026 |
| Truist Securities | Maintained | Buy | $42 $45 | Apr 30, 2026 |
| B of A Securities | Maintained | Buy | $38 $42 | Apr 9, 2026 |
| Piper Sandler | Reiterated | Overweight | $40 $41 | Mar 4, 2026 |
| Truist Securities | Maintained | Buy | $38 $42 | Feb 18, 2026 |
| Goldman Sachs | Maintained | Buy | $36 $45 | Feb 9, 2026 |
| Barclays | Maintained | Overweight | $35 $38 | Jan 30, 2026 |
| Scotiabank | Maintained | Sector Outperform | $35 $40 | Jan 29, 2026 |
| Truist Securities | Maintained | Buy | $36 $38 | Jan 29, 2026 |
| Jefferies | Maintained | Buy | $29 $40 | Jan 6, 2026 |
| Piper Sandler | Maintained | Overweight | $30 $40 | Dec 22, 2025 |
| Goldman Sachs | Maintained | Buy | $31 $35 | Dec 19, 2025 |
| JP Morgan | Maintained | Overweight | $28 $35 | Dec 16, 2025 |
| B of A Securities | Maintained | Buy | $29 $32 | Dec 9, 2025 |
149 filings from 25 insiders · 3 buy / 6 sell over 6m
Officers and directors of TEVA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MIGNONE ROBERTODirector | Sellindirect | 367.6k | $39.06 | $14.36M | Sep 18, 2026 |
| Savage BrianOfficer, Interim Chief Legal Officer | Exercise | 4.5k | $34.70 | $156k | Sep 18, 2026 |
| Savage BrianOfficer, Interim Chief Legal Officer | Sell | 4.5k | $38.69 | $174k | Sep 18, 2026 |
| Savage BrianOfficer, Interim Chief Legal Officer | Sell | 2.5k | $39.15 | $99k | Sep 18, 2026 |
| Savage BrianOfficer, Interim Chief Legal Officer | Sell | 314 | $38.70 | $12k | Sep 18, 2026 |
| Savage BrianOfficer, Interim Chief Legal Officer | ExerciseStock Options (right to buy) | 4.5k | $34.70 | $156k | Sep 18, 2026 |
| WEISS AMIROfficer | Exercise | 2.5k | $19.61 | $49k | Aug 21, 2026 |
| WEISS AMIROfficer | Sell | 9.4k | $37.61 | $355k | Aug 21, 2026 |
| SATCHI-FAINARO RONITDirector | Sell | 415 | $37.25 | $15k | Aug 21, 2026 |
| LIPPMAN EVANOfficer | Sell | 18.6k | $36.57 | $680k | Aug 17, 2026 |
| ZAKS TAL ZVIDirector | Sell | 17 | $34.87 | $593 | Aug 5, 2026 |
| HUGHES ERIC AOfficer | Other | 52.7k | — | — | Aug 3, 2026 |
| JOVER PLACIDOfficer | Other | 12.8k | — | — | Aug 3, 2026 |
| HUGHES ERIC AOfficer | Sell | 25.6k | $34.88 | $892k | Aug 3, 2026 |
| JOVER PLACIDOfficer | Sell | 12.8k | $34.88 | $447k | Aug 3, 2026 |
| SHIELDS MATTHEWOfficer | Sell | 10.0k | $32.19 | $322k | Jun 18, 2026 |
| KALIF ELIYAHU SHARONChief Financial Officer | Sell | 106.6k | $34.10 | $3.63M | Jun 11, 2026 |
| FRANCIS RICHARD DChief Executive Officer | Other | 13.0k | — | — | Jun 5, 2026 |
| NISEN PERRY DDirector | Other | 14.5k | — | — | Jun 5, 2026 |
| MIGNONE ROBERTO A.Director | Other | 14.5k | — | — | Jun 5, 2026 |
No analyst notes on TEVA yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 8 | 1 | 0 | 0 | Buy1.77 |
| 1 mo ago | 3 | 4 | 1 | 0 | 0 | Buy1.75 |
Members whose judged calls on TEVA have played out most reliably.
No settled calls on TEVA yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice